I think you have hammered on the correct point. These patients had not responded to any of the SOC. They had no other options. A CR and SD with mid dose is an amazing result for both these patients and shareholders.
Have a look at how some CarT have been given expedited approvals after phase 2 trials with T cell tech. Those drugs have many adeverse events (a recent on with AE rate of 79%).
For IMU have a safe drug, with these kind of results is a fantastic place to be. And to think there are still another two drugs to start trials!
Media Thread, page-854
-
- There are more pages in this discussion • 13,600 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.002(3.51%) |
Mkt cap ! $402.5M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.7¢ | 5.4¢ | $1.042M | 18.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 628179 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 897037 | 6 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |